News

Amendment of the Chips JU Work Programme 2023-2027

Published on | 1 year ago

Programmes Digital, Industry & Space Semiconductors

Please note that that the latest amendment of the Chips JU Work Programme 2023-2027 has been adopted. 

The following updates for call HORIZON-JU-Chips-2024-1-IA are introduced:

  • Appendix 3 “Activities Launched in 2024 for the Non-Initiative Part.”
    Section 2.3 “National Budgets for the call 2024”. The amount for some of the countries has been updated.
    In-text Annex 4 to appendix 3: “Country specific eligibility rules” have been added for some countries and amended for a country.

The following updates for call HORIZON-JU-Chips-2024-2-RIA are introduced:

  • Appendix 3 “Activities Launched in 2024 for the Non-Initiative Part.”
    Section 2.3 “National Budgets for the call 2024”. The amount for some of the countries has been updated.
    In-text Annex 4 to appendix 3: “Country specific eligibility rules” have been added for some countries and amended for a country.

The following updates for call HORIZON-JU-Chips-2024-3-RIA are introduced:

  • Section 2.9 “Call HORIZON-Chips-2024-3-RIA: Joint call with Korea on Heterogeneous integration and neuromorphic computing technologies for future semiconductor components and systems”.In the section related to “Selection” amended the requirement for minimum number of states. 
  • Annex 1 “General Annexes for the KDT calls 2024”. Updated reference to the Commission decision setting the general conditions applicable to calls and topics for grants under Horizon Europe

The updated Appendix 3 v6 has already been published on the website, in the “Multiannual Programme 2023-2027: https://www.chips-ju.europa.eu/mawp/

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1647 articles available search in articles 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.